Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
02/2003
02/06/2003WO2003009847A1 Substituted piperidines as modulators of the melanocortin receptor
02/06/2003WO2003009843A1 Use of thiazole derivatives for preparing a medicine for protecting mitochondria
02/06/2003WO2003009842A1 Injectable galenic formulation for use in a diagnosis or a photodynamic therapy and method for preparing same
02/06/2003WO2003009841A1 Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine
02/06/2003WO2003009835A2 Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
02/06/2003WO2003009828A1 Modifying the fatty acid composition of cell membranes of organs and tissues
02/06/2003WO2003009817A2 Stable lyophilized pharmaceutical formulation of igg antibodies
02/06/2003WO2003009815A2 Compositions and methods for modulating blood-brain barrier transport
02/06/2003WO2003009809A2 Cancer treatment with gö6976 and its related compounds
02/06/2003WO2003009807A2 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods
02/06/2003WO2003009779A2 Delivery of therapeutic capable agents
02/06/2003WO2003009778A2 Methods and devices for delivery of therapeutic capable agents with variable release profile
02/06/2003WO2003009777A2 Delivery of therapeutic capable agents
02/06/2003WO2003009741A2 Methods for treating joint inflammation, pain, and loss of mobility
02/06/2003WO2003000256A9 Substituted oxazolidinones for combinational therapy
02/06/2003WO2002096433A9 Methods for treating delirium using glucocorticoid receptor-specific antagonists
02/06/2003WO2002096423A3 Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways
02/06/2003WO2002096420A3 Method for treating nerve injury caused by surgery
02/06/2003WO2002085337B1 Micellar drug delivery systems for hydrophobic drugs
02/06/2003WO2002079146A3 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
02/06/2003WO2002070516A3 Cyclopropaheterocycles as non-nucleoside reverse transcriptase inhibitors
02/06/2003WO2002070001A3 Use of lp82 to treat hematopoietic disorders
02/06/2003WO2002067910A3 The use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
02/06/2003WO2002067851A3 Method for treating fibrotic diseases or other indications iiic
02/06/2003WO2002064586A3 Heterocyclic inhibitors of erk2 and uses thereof
02/06/2003WO2002060950A3 Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
02/06/2003WO2002059112A3 Pyrazole compounds useful as protein kinase inhibitors
02/06/2003WO2002055065A3 Use of an ltb4 antagonist for the treatment and/or prevention of diseases caused by increased expression of mucin genes
02/06/2003WO2002049666A3 Mycoplasma hyopneumoniae bacterin vaccine
02/06/2003WO2002048134A3 Di-substituted aminomethyl chroman derivative beta-3 adrenoreceptor agonists
02/06/2003WO2002046194A3 Substituted imidazopyridines
02/06/2003WO2002046172A3 Substituted 1, 3, 5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis
02/06/2003WO2002046141A3 Coumpounds of the formula r1-x-y-z-nr2r3 as abca-1 elevating agents against coronary artery disease or atherosclerosis
02/06/2003WO2002041843A3 Antiinflammation agents
02/06/2003WO2002039995A9 Combination therapy for estrogen-dependent disorders
02/06/2003WO2002030470A9 Methods and compositions for nucleic acid delivery
02/06/2003WO2002028904A3 Human anti-cd40 antibodies
02/06/2003WO2002020722A3 Methods and compositions for in vitro targeting
02/06/2003WO2002019963A3 Synthetic erythropoiesis stimulating proteins
02/06/2003WO2002016413A8 Cripto tumour polypeptide
02/06/2003WO2002014470A3 Expression of herstatin, an alternative her-2/neu product, in cells that express either p185her-2 or the egf receptor inhibits receptor activity and cell growth
02/06/2003WO2002007733A3 Method for enhancing bone mineral density gain by administration of raloxifene
02/06/2003WO2001088199A3 Identification and modulationof of a t helper-1 and t helper-2 cells
02/06/2003WO2001066139A9 Use of a compound that selectively binds to cd123 to impair hematologic cancer progenitor cell
02/06/2003WO2001047946A3 GFRα1-RET SPECIFIC AGONISTS AND METHODS THEREFOR
02/06/2003US20030028905 Mutant forms of the TGF-beta type II receptor which bind all TGF-beta isoforms
02/06/2003US20030028639 Access control system
02/06/2003US20030028028 1-oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels
02/06/2003US20030028018 Treating diseases characterized by activity of vascular endothelial growth factor receptor tyrosine kinases such as cancer
02/06/2003US20030028006 Cytokine receptor common gamma chain like
02/06/2003US20030027999 143 human secreted proteins
02/06/2003US20030027861 6-Methoxy-2-naphthylacetic acid prodrugs
02/06/2003US20030027860 6-Methoxy-2-naphthylacetic acid prodrugs
02/06/2003US20030027859 3-aryl-2-hydroxypropionic acid derivative I
02/06/2003US20030027847 Carboxyformylacetamide derivatives for treatment of AIDS or ARC
02/06/2003US20030027845 Ether derivatives useful as inhibitors of PDE4 isozymes
02/06/2003US20030027840 Estrogen receptor modulators
02/06/2003US20030027839 Farnesyl protein transferase inhiitors for treating breast cancer
02/06/2003US20030027835 Trimebutine, N-desmethyltrimebutine, their metabolites or their stereoisomers and an opioid analgesic for treating pain or nociception.
02/06/2003US20030027831 Arylpiperzine derivatives are useful for treatment of anxiety, depression, hypertension, cognitive disorders, sexual dysfunction, brain trauma, memory loss, eating disorders, obesity, substance abuse, and obsessive-compulsive diseases
02/06/2003US20030027823 N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
02/06/2003US20030027821 Administering 2-oxy substituted benzoxazin-5-one derivative to a human or animal for the prevention or treatment of obesity or an obesity related disorder
02/06/2003US20030027820 Method for treating fibrotic diseases or other indications V
02/06/2003US20030027818 Treatment of cancers
02/06/2003US20030027814 Bis(5-aryl-2-pyridyl) compound having excellent immunoglobulin (IgE) antibody production inhibiting activity, useful for the prevention or treatment of allergic immune diseases
02/06/2003US20030027812 Useful for treating or preventing a disorder or condition selected from hypertension, depression, anxiety, phobias, post trauma stress, sexual disfunction, eating disorder, obesity, Alzheimer's disease, Parkinson's disease etc.
02/06/2003US20030027808 Imidazoly-5-yl)methyl-2-quinolinone derivatives, together with platinum coordination compound selected from cisplatin or carboplatin; useful as anticarcinogenic agent
02/06/2003US20030027807 Vitronectin receptor antagonists, their preparation and their use
02/06/2003US20030027806 Triptolide analogs for the treatment of autoimmune and inflammatory disorders
02/06/2003US20030027804 Administering to the mammal a menopause disorder effective amount of an orally deliverable pharmaceutically- acceptable sex hormone binding globulin synthesis inhibiting agent, and at least one of a non-orally deliverable steroids
02/06/2003US20030027800 LPA receptor agonists and antagonists and methods of use
02/06/2003US20030027794 N-heterocyclic derivatives as NOS inhibitors
02/06/2003US20030027786 Lipase inhibiting composition
02/06/2003US20030027785 Administering to a subject a purinergic receptor agonist in an amount therapeutically effective to alter the amount or formulation of synovial fluids
02/06/2003US20030027783 Introducing into the cell an RNA comprising a double stranded structure having nucleotide sequence which is substantially identical to part of target gene and which is derived from an endogenous template; verifying inhibition of expression
02/06/2003US20030027774 For diagnosis and therapy of tuberculosis
02/06/2003US20030027772 Composition containing at least one inhibitor of the enzyme 3-beta-HSD
02/06/2003US20030027746 Useful in the development of human therapeutics and diagnostic formulations
02/06/2003US20030027299 Biochemical conjugate for use in the treatment or prevention of stroke, heart defect, veinous thrombosis, sepsis and embolism
02/06/2003US20030027253 Nucleotides equences codin polypeptide for use in the treatment of cancer
02/06/2003US20030027248 Human cDNAs and proteins and uses thereof
02/06/2003US20030027243 Screening or testing fungicide; obtain fungal protein sample, incubate with test modulator, monitor interaction between fungicide and protein, adjustment in protein activity indicate fungicide
02/06/2003US20030027230 Detection of antiproliferative agents for treatment of ovarian cancer; obtain cells, incubate with modulator, monitor cells for reduction in cancer activity, reduction in cancer activity indicates antiproliferative agents
02/06/2003US20030027188 SLC7s as modifiers of the p53 pathway and methods of use
02/06/2003US20030027164 Novel human nucleic acid molecules and polypeptides encoding a novel human ion channel expressed in spinal cord and brain
02/06/2003US20030027161 Human cDNAs and proteins and uses thereof
02/06/2003US20030027158 Novel nucleic acid sequences encoding human breast tumor-associated protein 47-like polypeptides
02/06/2003US20030027151 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of bone disorders
02/06/2003US20030026861 Anticancer agents; from soybeans
02/06/2003US20030026820 Use of a compositon containing an effective quantity of at least one ion chelating agent for increasing the tolerance threshold of a sensitive or intolerant skin
02/06/2003US20030026801 Methods for enhancing antibody-induced cell lysis and treating cancer
02/06/2003US20030026796 Method for treating a subject suffering from conditions associated with an extracellular zinc sphingomyelinase
02/06/2003US20030026789 Anticancer agents
02/06/2003CA2455602A1 Protein kinase inhibitors comprising atp mimetics conjugated to peptides or peptidomimetics
02/06/2003CA2455580A1 Multipotent stem cells from peripheral tissues and uses thereof
02/06/2003CA2454903A1 Substituted piperazines as modulators of the melanocortin receptor
02/06/2003CA2454805A1 Probiotic lactobacillus casei strains
02/06/2003CA2454802A1 Novel class ii cytokine receptors and uses thereof
02/06/2003CA2454734A1 New isolated dendritic cells, a process for preparing the same and their use in pharmaceutical compositions
02/06/2003CA2454564A1 Process for the preparation of 2-(2-(4-(bis(4-fluorophenyl)methyl)-piperazin-1-yl)ethoxy)acetic acid derivatives or corresponding salt forms thereof and intermediates therefor
1 ... 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 ... 1564